Diabetes Drug Class Shows No Clear Bone Risk in New Scan-Based Study

One of the most widely prescribed families of diabetes drugs has faced a persistent question since it entered clinical practice: does it quietly weaken the skeleton? Sodium-glucose cotransporter-2 inhibitors, known universally as SGLT2 inhibitors, transformed the treatment of type 2 diabetes mellitus by forcing the kidneys to flush excess glucose out of the body through urine. Along the way they delivered unexpected benefits for the heart and kidneys, cementing their place in modern treatment guidelines. Yet endocrinologists have remained uneasy about reports suggesting these agents might accelerate bone mineral loss, particularly in older patients whose skeletons are already vulnerable. A new observational study from Türkiye now offers a measure of reassurance, finding no statistically significant link between SGLT2 inhibitor use and osteoporosis or reduced bone mineral density in patients with type 2 diabetes, while candidly acknowledging that its modest sample size leaves room for doubt.

The research, led by Muhammet Fatih Şahin of the Department of Internal Medicine at Kestel State Hospital in Bursa and colleagues at collaborating institutions, was published in BMC Endocrine Disorders as an open-access research article. The team set out to answer a deceptively simple question: among people with type 2 diabetes who undergo clinically indicated dual-energy X-ray absorptiometry, do those taking SGLT2 inhibitors show worse bone health than those who do not? To address it, the investigators assembled a primary analytical cohort of 56 patients with type 2 diabetes who were referred for DEXA scanning between June 2025 and February 2026. Of these, 31 patients were not using SGLT2 inhibitors and 25 were. A separate group of 44 participants without diabetes was recruited purely for secondary, descriptive comparisons, providing a reference point for how bone health parameters distribute in people free of the metabolic disease.

The choice of measurement technique matters enormously in this field, and the study leaned on the gold standard. Dual-energy X-ray absorptiometry, or DEXA, works by firing two X-ray beams of different energies through the body and measuring how much each is attenuated by bone tissue. Because calcium in bone absorbs X-rays far more efficiently than soft tissue, the differential attenuation allows clinicians to calculate bone mineral density with remarkable precision at clinically relevant sites. The researchers focused on the lumbar spine and the femoral neck, the narrow segment of the thigh bone just below the hip joint where fractures are both common and devastating. Each participant received a T-score at these sites, a number that expresses bone density as a comparison against the average peak bone mass of a healthy young adult. A T-score of minus 2.5 or lower at either site defines osteoporosis, while values between minus 1.0 and minus 2.5 fall into the intermediate territory of osteopenia.

The headline result was a statistical null. Osteoporosis, defined as a T-score of minus 2.5 or below at the lumbar spine or femoral neck, was present in 32.3 percent of the patients with type 2 diabetes who were not taking SGLT2 inhibitors and in 36.0 percent of those who were, a difference that was statistically indistinguishable with a p-value of 0.769. When the investigators moved beyond raw prevalence and applied logistic regression, adjusting for age, sex, and body mass index, the odds ratio for osteoporosis associated with SGLT2 inhibitor exposure came out at 1.169 with a 95 percent confidence interval stretching from 0.328 to 4.170, and a p-value of 0.810. An odds ratio of 1.0 would indicate no effect at all; the observed value of 1.169 hints at a modestly elevated risk, but the confidence interval is so wide that it comfortably spans everything from a strong protective effect to a more than fourfold increase in risk. In plain terms, the data cannot tell readers which direction, if any, the true effect points.

The null findings extended across every secondary outcome the team examined. There was no significant association between SGLT2 inhibitor use and the worst T-score recorded for each patient, nor with the site-specific T-scores at the lumbar spine or femoral neck. Actual bone mineral density measurements at both anatomical sites likewise showed no meaningful differences between users and non-users of the drug class. Even when patients were sorted into broader bone mineral density risk categories, normal, osteopenic, or osteoporotic, based on the worse of their two T-scores, the distribution did not differ significantly between the groups. A supplementary analysis incorporating the non-diabetic comparison group, evaluated with a Fisher–Freeman–Halton exact test, found no significant difference in bone mineral density category distribution across all three groups, with a p-value of 0.809. For a drug class that has been shadowed by skeletal concerns, the consistency of the null results across so many related endpoints is itself informative.

Why, then, did the skeletal question arise in the first place? The biological plausibility of harm has never been trivial. SGLT2 inhibitors induce a mild state of glucosuria, and the resulting caloric and fluid shifts alter phosphate handling, insulin secretion, and parathyroid hormone dynamics, all of which participate in the delicate regulation of bone remodeling. Some earlier observational studies and post-marketing analyses raised flags about fracture risk, particularly with canagliflozin, prompting regulators to add warnings to drug labels. At the same time, type 2 diabetes itself complicates the picture in a way that standard DEXA measurements can underappreciate. People with diabetes can sustain fragility fractures at bone densities that would be considered safe in the general population, a phenomenon thought to reflect impaired bone quality, altered collagen cross-linking, and the added danger of hypoglycemia-related falls. Any study of diabetes drugs and bone health therefore has to contend with a disease process that already distorts the relationship between measured density and actual fracture risk.

The authors of the new study are careful, and appropriately so, about what their results can and cannot support. In their conclusion they state that no statistically significant association was detected between SGLT2 inhibitor use and DEXA-derived bone health outcomes in patients with type 2 diabetes, but they immediately qualify this by noting that the limited sample size and the wide confidence intervals preclude excluding clinically meaningful associations. They call for larger prospective studies to settle the question. This is the honest language of exploratory research: a study of 56 patients simply lacks the statistical power to detect anything but a very large effect. With confidence intervals as broad as those reported here, a true doubling of osteoporosis risk could hide within the data undetected. Readers and clinicians should therefore interpret the findings as absence of evidence rather than evidence of absence, a distinction that matters when treatment decisions hang in the balance.

The study’s design also carries limitations worth understanding. As an observational, cross-sectional analysis conducted at a single hospital department, it captured patients at one moment in time rather than following them as bone density evolved. Patients were not randomized to receive SGLT2 inhibitors, so the possibility of confounding by indication, where the reasons a clinician chose a particular drug correlate with other health factors, cannot be fully excluded even with adjustment for age, sex, and body mass index. The duration of SGLT2 inhibitor exposure among users was not a central variable in the reported analysis, yet skeletal effects of any drug typically accumulate over years. The inclusion of a non-diabetic comparison group adds descriptive context, but the core inference rests on the 56 patients with diabetes divided into two modest groups. Ethics approval was granted by the Institutional Ethics Committee of Bursa Yüksek İhtisas Training and Research Hospital, and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki, underscoring that the study met standard procedural safeguards even within its constrained scope.

For the millions of people taking SGLT2 inhibitors worldwide, the practical message is one of cautious reassurance rather than definitive clearance. The study found osteoporosis to be strikingly common in this population regardless of medication, affecting roughly a third of patients in both groups, which reinforces the importance of bone health screening for people with type 2 diabetes independent of their glucose-lowering regimen. Clinicians already weigh fracture risk when selecting diabetes therapies, and these findings do not demand a change in that calculus. What the research does provide is a template for the kind of work that must come next: large, prospective cohorts with longitudinal DEXA monitoring, careful documentation of drug duration and dose, and ideally fracture outcomes rather than surrogate density measures alone. Until such studies arrive, the skeleton’s verdict on SGLT2 inhibitors remains open, but the scales have tilted slightly, and measurably, toward the reassuring side.

Subject of Research: The association between SGLT2 inhibitor use and DEXA-derived bone health parameters in patients with type 2 diabetes mellitus

Article Title: SGLT2 inhibitor use and DEXA-derived bone health in type 2 diabetes mellitus

Article References: Şahin, M. F., Şahin, A., Dinar, A. B. K., Avul, S., İzeet, S. N., & Erol, A. (2026). SGLT2 inhibitor use and DEXA-derived bone health in type 2 diabetes mellitus. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02633-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02633-z

Keywords: SGLT2 inhibitors, type 2 diabetes, osteoporosis, bone mineral density, DEXA, T-score, BMC Endocrine Disorders, observational study, endocrinology, fragility fractures, glucosuria, bone health